Video Source: http://www.adyo.org/home.html
* addiction, recovery and yoga* |
~~~~~~~~~~~~~~~~~~~SupportGroups.com provides a support
network for those facing life's challenges. Click on the following links to get the support in a confidential, caring environment ~~~~~~~~~~~~~~~~~~~~~~~~~~~~ |
What is MAT? (Medication-Assisted Treatment)
MAT is any treatment for opioid addiction that includes a medication (e.g., methadone, buprenorphine, levo-alpha acetyl methadol [LAAM], naltrexone) approved by the U.S. Food and Drug Administration (FDA) for opioid addiction detoxification or maintenance treatment. MAT may be provided in an OTP or an OTP medication unit (e.g., pharmacy, physician's office) or, for buprenorphine, a physician's office or other health care setting. Comprehensive maintenance, medical maintenance, interim maintenance, detoxification, and medically supervised withdrawal are types of MAT.
What is an OTP? (Opioid Treatment Program)
An OTP is any treatment program certified by the Substance Abuse and Mental Health Services Administration (SAMHSA) in conformance with 42 Code of Federal Regulations (CFR), Part 8, to provide supervised assessment and medication-assisted treatment for patients who are opioid addicted. An OTP can exist in a number of settings, including, but not limited to, intensive outpatient, residential, and hospital settings. Types of treatment can include medical maintenance, medically supervised withdrawal, and detoxification, either with or without various levels of medical, psychosocial, and other types of care.
What is an OTP? (Opioid Treatment Program)
An OTP is any treatment program certified by the Substance Abuse and Mental Health Services Administration (SAMHSA) in conformance with 42 Code of Federal Regulations (CFR), Part 8, to provide supervised assessment and medication-assisted treatment for patients who are opioid addicted. An OTP can exist in a number of settings, including, but not limited to, intensive outpatient, residential, and hospital settings. Types of treatment can include medical maintenance, medically supervised withdrawal, and detoxification, either with or without various levels of medical, psychosocial, and other types of care.
OTPs can provide several treatment options:
- Maintenance treatment combines pharmacotherapy with a full program of assessment, psychosocial intervention, and support services; it is the approach with the greatest likelihood of long-term success for many patients.
- Medical maintenance treatment is provided to stabilize patients and may include long-term provision of methadone, buprenorphine, LAAM, or naltrexone, with a reduction in clinic attendance and other services. A patient can receive medical maintenance at an OTP, after he or she is stabilized fully. The patient usually must complete a comprehensive treatment program first. The decision about whether to provide medical maintenance must be made by a licensed practitioner. A designated medication unit (e.g., physician's office, pharmacy, long-term care facility) affiliated with an OTP can provide some medical maintenance services. To reduce clinic attendance—a key feature of medical maintenance—patients must qualify, subject to variations in State regulations (which may be more stringent than Federal regulations), to receive 7- to 14-day supplies of methadone for take-home dosing after 1 year of continuous treatment and 15- to 30-day supplies after 2 years of continuous treatment in an OTP.
- Detoxification from short-acting opioids involves medication and, perhaps, counseling or other assistance to stabilize patients who are opioid addicted by withdrawing them in a controlled manner from the illicit opioids.
- Medically supervised withdrawal treatment involves the controlled tapering of treatment medication for patients who want to remain abstinent from opioids without the assistance of medication.
SOURCE: http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=hssamhsatip&part=A82676
State Opioid Treatment Authoritites
|
Opiate Addiction and Treatment:
|
U.S. Dept of Health and Human Services
Guidance To Opioid Treatment Programs (OTP's)
(Click On SOURCE URL at bottom of screen to read articles)
-----------------------------------------------------------------------------------------
SAMHSA Announcements and Advisories
- CSAT Fentanyl-Heroin Fact Sheet, June 2006 (PDF, 36 KB)
- OTP Mortality Report Form Letter, November 2008 (PDF, 184 KB)
- SAMHSA guidance regarding labeling of take-home medication bottles, May 2008 (PDF, 441 KB)
- Limitation on availability of methadone hydrochloride tablets, 40 mg (dispersible),
December 2007 (PDF 890 KB) - Importance of Determining Initial Methadone Dose, September 2007 (PDF 115 KB)
- Announcement of Updated OTP Accreditation Guidelines, August 2007 (PDF 22 KB)
- New limit on number of buprenorphine patients per physician, January 2007 (PDF, 257 KB)
- Revised Methadone FDA Labeling, December 2006 (PDF, 89 KB)
- Guidance to OTPs affected by Hurricane Katrina, November 2005 (PDF, 87 KB)
- OTP holiday closure guidance, November 2005 (PDF, 49 KB)
- Adequacy of oral fluid testing in OTPs, July 2003 (PDF, 543 KB)
- Status of buprenorphine, September 2002 (PDF, 268 KB)
- Methadone medical maintenance, March 2002 (PDF, 65 KB)
- Announcement of approval of OTP accrediting organizations, December 2001
SOURCE: http://www.dpt.samhsa.gov/index.aspx
Disclaimer: The contents of OpioidAddiction.weebly.com/HALO inc. are for general informational purposes only and are not intended to substitute for professional or medical evaluation, diagnosis, treatment, or advice. Users of this site are encouraged to contact your professional healthcare provider for medical assistance regarding addictive disorders, general health problems, mental health problems, and any & all health-related questions.